Valor202020212022202320242025TTMGastos comerciales, generales y administrativos22.08 B24.66 B24.77 B21.51 B22.87 B23.68 B24.6 BInvestigación y desarrollo12.16 B14.71 B14.6 B483 M1.84 B109 M14.97 BBeneficio operativo14.67 B18.65 B18.37 B30.43 B31.49 B35.12 B16.9 BTotal de ingresos no operativos-3 B-672 M-1.71 B-5.74 B-3.58 B8.01 B547 MGastos por intereses, netos de intereses capitalizados201 M183 M276 M772 M755 M971 M1.04 BIngresos no operativos, una vez deducidos los gastos por intereses-299 M-366 M-114 M123 M363 M-169 M-86 MIngresos/gastos extraordinarios-2.9 B-489 M-1.87 B-6.63 B-4.69 B7.21 B-406 MBeneficio antes de impuestos16.5 B22.78 B21.73 B15.06 B16.69 B32.58 B24.94 BParticipación en los beneficios———————Impuestos1.78 B1.9 B3.78 B1.74 B2.62 B5.78 B3.9 BParticipación minoritaria———————Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas14.71 B20.88 B17.94 B13.33 B14.07 B26.8 B21.04 BOperaciones suspendidas———21.83 B00—Beneficio neto14.71 B20.88 B17.94 B35.15 B14.07 B26.8 B21.04 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas14.71 B20.88 B17.94 B35.15 B14.07 B26.8 B21.04 BBeneficio básico por acción5.597.936.8313.885.8411.138.73Beneficio por acción diluido5.517.816.7313.725.7911.038.63Número medio de acciones ordinarias2.63 B2.63 B2.63 B2.53 B2.41 B2.41 B—Acciones diluidas2.67 B2.67 B2.66 B2.56 B2.43 B2.43 B—EBITDA21.9 B25.95 B25.3 B37.91 B38.83 B42.62 B21.03 BEBIT14.67 B18.65 B18.37 B30.43 B31.49 B35.12 B16.9 BCosto de los ingresos28.43 B29.86 B31.09 B26.55 B27.47 B30.26 B31 BOtros costes de producción———————Amortización y depreciación (flujo de caja)7.23 B7.39 B6.97 B7.49 B7.34 B7.5 B7.74 B
Johnson & Johnson Common Stock
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey.
The company operates 2 divisions: Innovative Medicine and MedTech. Major products produced by the Innovative Medicine division are CARVYKTI for multiple myeloma; DARZALEX, also for multiple myeloma; ERLEADA, for prostate cancer; REMICADE, for inflammatory diseases; SIMPONI/SIMPONI ARIA, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; STELARA, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; TREMFYA, for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; INVEGA SUSTENNA/XEPLION, for schizophrenia; SPRAVATO, a nasal spray for depression; OPSUMIT /OPSYNVI for pulmonary arterial hypertension; and UPTRAVI for pulmonary arterial hypertension. The MedTech division produces products used for cardiovascular, orthopaedics, surgery, and vision treatments.
The company is ranked 48th on the Fortune 500 and 42nd on the Forbes Global 2000.